Cargando…

Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD)

BACKGROUND: Treatment of spasticity poses a major challenge in amyotrophic lateral sclerosis (ALS) patient management. Delta-9-tetrahydrocannabinol (THC):cannabidiol (CBD) oromucosal spray (THC:CBD), approved for the treatment of spasticity in multiple sclerosis, serves as a complementary off-label...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meyer, Thomas, Funke, Andreas, Münch, Christoph, Kettemann, Dagmar, Maier, André, Walter, Bertram, Thomas, Annett, Spittel, Susanne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732193/ https://www.ncbi.nlm.nih.gov/pubmed/31493784 http://dx.doi.org/10.1186/s12883-019-1443-y

Ejemplares similares

The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis‐related spasticity
por: Celius, Elisabeth G., et al.
Publicado: (2018)

A protocol for the delivery of cannabidiol (CBD) and combined CBD and ∆(9)-tetrahydrocannabinol (THC) by vaporisation
por: Solowij, Nadia, et al.
Publicado: (2014)

Are adverse effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?
por: Lachenmeier, Dirk W., et al.
Publicado: (2023)

The influence of physiotherapy intervention on patients with multiple sclerosis–related spasticity treated with nabiximols (THC:CBD oromucosal spray)
por: Grimaldi, Alessandro Enrico, et al.
Publicado: (2019)

Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition
por: Arkell, Thomas R., et al.
Publicado: (2019)

Conversion of Cannabidiol (CBD) into Psychotropic Cannabinoids Including Tetrahydrocannabinol (THC): A Controversy in the Scientific Literature
por: Golombek, Patricia, et al.
Publicado: (2020)

The Effect of Orally Administered Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) on Obesity Parameters in Mice
por: Eitan, Adi, et al.
Publicado: (2023)

Variability of Multiple Sclerosis Spasticity Symptoms in Response to THC:CBD Oromucosal Spray: Tracking Cases through Clinical Scales and Video Recordings
por: Flachenecker, Peter, et al.
Publicado: (2018)

A Review of Scientific Evidence for THC:CBD Oromucosal Spray (Nabiximols) in the Management of Chronic Pain
por: Überall, Michael A
Publicado: (2020)

Differential inflammatory profile in the lungs of mice exposed to cannabis smoke with varying THC:CBD ratio
por: Haidar, Zahraa, et al.
Publicado: (2023)

Integration of Cannabis Extract Tetrahydrocannabinol:Cannabidiol in an Interdisciplinary Therapy Setting: A Case of Chronic Multilocular Pain Disorder
por: Romeyke, Tobias, et al.
Publicado: (2022)

Patient-Reported Outcome of Physical Therapy in Amyotrophic Lateral Sclerosis: Observational Online Study
por: Meyer, Robert, et al.
Publicado: (2018)

Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis
por: Hutten, Nadia R. P. W., et al.
Publicado: (2022)

A randomised controlled cross-over double-blind pilot study protocol on THC:CBD oromucosal spray efficacy as an add-on therapy for post-stroke spasticity
por: Marinelli, Lucio, et al.
Publicado: (2017)

Proteome-Wide Profiling Using Sample Multiplexing of a Human Cell Line Treated with Cannabidiol (CBD) and Tetrahydrocannabinol (THC)
por: Abyadeh, Morteza, et al.
Publicado: (2023)

Motor neuron development in zebrafish is altered by brief (5-hr) exposures to THC (∆(9)-tetrahydrocannabinol) or CBD (cannabidiol) during gastrulation
por: Ahmed, Kazi T., et al.
Publicado: (2018)

Pharmacokinetic and Safety Evaluation of Various Oral Doses of a Novel 1:20 THC:CBD Cannabis Herbal Extract in Dogs
por: Chicoine, Alan, et al.
Publicado: (2020)

An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed Sativex(®) (THC:CBD, nabiximols) oromucosal spray
por: Etges, Tilden, et al.
Publicado: (2016)

Differences in Inhibitory Control and Resting Brain Metabolism between Older Chronic Users of Tetrahydrocannabinol (THC) or Cannabidiol (CBD)—A Pilot Study
por: Rudroff, Thorsten, et al.
Publicado: (2022)

Comment on Lachenmeier et al (2020) “Are side effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?”: disputation on various points in the publication
por: Kruse, Daniel, et al.
Publicado: (2020)

A Critical Review of the Role of the Cannabinoid Compounds Δ(9)-Tetrahydrocannabinol (Δ(9)-THC) and Cannabidiol (CBD) and their Combination in Multiple Sclerosis Treatment
por: Jones, Éamon, et al.
Publicado: (2020)

Study of Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) extraction FROM dried oral fluid spots (DOFS) and LC–MS/MS detection
por: Gorziza, Roberta, et al.
Publicado: (2021)

Evaluation of the preclinical analgesic efficacy of naturally derived, orally administered oil forms of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and their 1:1 combination
por: Linher-Melville, Katja, et al.
Publicado: (2020)

Efficacy of Δ(9) -Tetrahydrocannabinol (THC) Alone or in Combination With a 1:1 Ratio of Cannabidiol (CBD) in Reversing the Spatial Learning Deficits in Old Mice
por: Nidadavolu, Prakash, et al.
Publicado: (2021)

Biomechanical Effects of Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD), the Major Constituents of Cannabis, in a Sprague Dawley Rat Achilles Tendon Surgical Repair Model
por: Stauch, Chris M., et al.
Publicado: (2020)

Differential Effects of D9 Tetrahydrocannabinol (THC)- and Cannabidiol (CBD)-Based Cannabinoid Treatments on Macrophage Immune Function In Vitro and on Gastrointestinal Inflammation in a Murine Model
por: Yekhtin, Zhanna, et al.
Publicado: (2022)

Pilot clinical and pharmacokinetic study of Δ(9)-Tetrahydrocannabinol (THC)/Cannabidiol (CBD) nanoparticle oro-buccal spray in patients with advanced cancer experiencing uncontrolled pain
por: Clarke, Stephen, et al.
Publicado: (2022)

Acceptance of Enhanced Robotic Assistance Systems in People With Amyotrophic Lateral Sclerosis–Associated Motor Impairment: Observational Online Study
por: Maier, André, et al.
Publicado: (2021)

Cannabidiol (CBD) and Δ(9)-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial
por: Suraev, Anastasia, et al.
Publicado: (2020)

O006 Acute effects of combined cannabidiol (CBD) and ∆9-tetrahydrocannabinol (THC) in insomnia disorder: A randomised, placebo-controlled trial using high-density EEG
por: Suraev, A, et al.
Publicado: (2022)

Comparison of the Effectiveness and Tolerability of Nabiximols (THC:CBD) Oromucosal Spray versus Oral Dronabinol (THC) as Add-on Treatment for Severe Neuropathic Pain in Real-World Clinical Practice: Retrospective Analysis of the German Pain e-Registry
por: Ueberall, Michael A, et al.
Publicado: (2022)

Biomechanical Effects of Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD), the Major Constituents of Cannabis, on Tendon to Tendon Healing in a Sprague Dawley Rat Achilles Tendon Surgical Repair Model
por: Stauch, Chris, et al.
Publicado: (2020)

CBD, a precursor of THC in e-cigarettes
por: Czégény, Zsuzsanna, et al.
Publicado: (2021)

Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry
por: Ueberall, Michael A, et al.
Publicado: (2019)

Long-Term Consequences of Adolescent Exposure to THC-Rich/CBD-Poor and CBD-Rich/THC-Poor Combinations: A Comparison with Pure THC Treatment in Female Rats
por: Gabaglio, Marina, et al.
Publicado: (2021)

Cannabidiol (CBD) in Cancer Management
por: O’Brien, Kylie
Publicado: (2022)

The Impact of THC and CBD in Schizophrenia: A Systematic Review
por: Ahmed, Saeed, et al.
Publicado: (2021)

Detection of Δ(9) THC in oral fluid following vaporized cannabis with varied cannabidiol (CBD) content: An evaluation of two point‐of‐collection testing devices
por: Arkell, Thomas R., et al.
Publicado: (2019)

Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)
por: Hardy, Janet, et al.
Publicado: (2020)

THC and CBD: Villain versus Hero? Insights into Adolescent Exposure
por: Pintori, Nicholas, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_17jvvf7auq9fvb763mk755lh4h